colestipol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	728	50925-79-6

Description:

Molecule	Description
Synonyms: colestipol cholestabyl cholestipol colestipol hydrochloride colestipol HCl	Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

colestipol
cholestabyl
cholestipol
colestipol hydrochloride
colestipol HCl

Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
April 4, 1977	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	111.95	21.12	191	4414	715175	62769242
Product physical issue	85.62	21.12	26	4579	4954	63479463
Fistula	43.10	21.12	19	4586	10374	63474043
Mucous stools	35.98	21.12	13	4592	4235	63480182
Vaginal abscess	35.97	21.12	8	4597	447	63483970
Product dose omission issue	35.46	21.12	62	4543	234251	63250166
Anal skin tags	34.86	21.12	8	4597	515	63483902
Infusion site streaking	34.83	21.12	8	4597	517	63483900
Clostridium difficile infection	33.51	21.12	23	4582	29899	63454518
Rectal fissure	32.89	21.12	8	4597	662	63483755
Intestinal obstruction	32.84	21.12	23	4582	30876	63453541
Vitamin D increased	32.40	21.12	8	4597	704	63483713
Feeding intolerance	31.74	21.12	8	4597	766	63483651
Procedural anxiety	31.72	21.12	8	4597	768	63483649
Product use complaint	30.40	21.12	10	4595	2464	63481953
Frequent bowel movements	28.91	21.12	19	4586	23003	63461414
Lactose intolerance	28.58	21.12	10	4595	2968	63481449
Cholangitis sclerosing	25.79	21.12	8	4597	1633	63482784
Haemorrhoids	24.74	21.12	17	4588	22133	63462284
Poor quality product administered	24.28	21.12	9	4596	3147	63481270
Flatulence	24.00	21.12	20	4585	34682	63449735
Gastrointestinal ulcer	23.57	21.12	8	4597	2167	63482250
Haematocrit increased	23.05	21.12	8	4597	2318	63482099
White blood cell disorder	22.38	21.12	8	4597	2526	63481891
Anorectal discomfort	22.06	21.12	8	4597	2631	63481786
Gingival swelling	21.35	21.12	9	4596	4409	63480008

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	63.10	23.76	75	1248	389837	34565771
Intestinal stenosis	24.17	23.76	7	1316	2179	34953429

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Diarrhoea	86.38	20.05	167	4345	880322	78859554
Fistula	53.64	20.05	22	4490	12918	79726958
Product physical issue	51.68	20.05	16	4496	4169	79735707
Vaginal abscess	38.74	20.05	8	4504	404	79739472
Anal skin tags	37.57	20.05	8	4504	469	79739407
Rectal fissure	36.92	20.05	9	4503	966	79738910
Infusion site streaking	36.76	20.05	8	4504	520	79739356
Mucous stools	36.65	20.05	13	4499	5149	79734727
Vitamin D increased	35.52	20.05	8	4504	609	79739267
Procedural anxiety	33.80	20.05	8	4504	758	79739118
Intestinal obstruction	33.41	20.05	24	4488	42996	79696880
Feeding intolerance	32.87	20.05	8	4504	852	79739024
Lactose intolerance	29.15	20.05	9	4503	2321	79737555
Clostridium difficile infection	29.06	20.05	22	4490	42663	79697213
Intestinal resection	28.73	20.05	10	4502	3747	79736129
Product use complaint	28.59	20.05	9	4503	2474	79737402
Cholangitis sclerosing	28.06	20.05	9	4503	2628	79737248
Frequent bowel movements	26.48	20.05	18	4494	29521	79710355
Large intestinal ulcer	26.35	20.05	10	4502	4787	79735089
Intestinal stenosis	24.94	20.05	9	4503	3745	79736131
COVID-19	23.23	20.05	36	4476	157638	79582238
Gingival swelling	23.14	20.05	9	4503	4600	79735276
Product dose omission issue	22.82	20.05	46	4466	247491	79492385
White blood cell disorder	22.51	20.05	8	4504	3184	79736692
Haemorrhoids	22.04	20.05	16	4496	29112	79710764
Gastrointestinal ulcer	21.92	20.05	8	4504	3438	79736438
Anorectal discomfort	21.55	20.05	8	4504	3603	79736273
Cystic fibrosis	20.99	20.05	8	4504	3872	79736004
Female genital tract fistula	20.88	20.05	9	4503	5966	79733910
Diverticulum	20.73	20.05	12	4500	14884	79724992
Haematocrit increased	20.69	20.05	8	4504	4026	79735850
Flatulence	20.58	20.05	18	4494	42706	79697170
Oesophageal pain	20.23	20.05	8	4504	4271	79735605

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AC02	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Bile acid sequestrants
FDA MoA	N0000175365	Bile-acid Binding Activity
CHEBI has role	CHEBI:35821	anticholesteremic drugs
MeSH PA	D000837	Anion Exchange Resins
MeSH PA	D000963	Antimetabolites
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D007475	Ion Exchange Resins
MeSH PA	D057847	Lipid Regulating Agents
MeSH PA	D064449	Sequestering Agents
FDA EPC	N0000180292	Bile Acid Sequestrant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Hyperlipidemia	indication	55822004	DOID:1168
Poisoning by digitalis glycoside	off-label use	12876009
Biliary Obstruction with Pruritus	off-label use
Constipation	contraindication	14760008	DOID:2089
Blood coagulation disorder	contraindication	64779008	DOID:1247
Hemorrhoids	contraindication	70153002	DOID:9746
Kidney disease	contraindication	90708001	DOID:557
Calculus in biliary tract	contraindication	266474003
Complete Biliary Obstruction	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4019692	VUID
N0000147784	NUI
D02113	KEGG_DRUG
37296-80-3	SECONDARY_CAS_RN
104485	RXNORM
4018086	VANDF
4019692	VANDF
C0009279	UMLSCUI
CHEBI:3814	CHEBI
CHEMBL1909303	ChEMBL_ID
CHEMBL1201474	ChEMBL_ID
DB00375	DRUGBANK_ID
D003084	MESH_DESCRIPTOR_UI
62816	PUBCHEM_CID
2738	INN_ID
K50N755924	UNII
4494	MMSL
83640	MMSL
d00744	MMSL
001217	NDDF
004708	NDDF
372811005	SNOMEDCT_US
55316001	SNOMEDCT_US
66971004	SNOMEDCT_US
26658-42-4	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0260	GRANULE, FOR SUSPENSION	5 g	ORAL	NDA	18 sections
Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0260	GRANULE, FOR SUSPENSION	5 g	ORAL	NDA	18 sections
Flavored Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0370	GRANULE, FOR SUSPENSION	5 g	ORAL	NDA	18 sections
Flavored Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0370	GRANULE, FOR SUSPENSION	5 g	ORAL	NDA	18 sections
Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0450	TABLET	1 g	ORAL	NDA	18 sections
Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0450	TABLET	1 g	ORAL	NDA	18 sections
Colestid	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0450	TABLET	1 g	ORAL	NDA	18 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2142	TABLET, FILM COATED	1 g	ORAL	ANDA	20 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2142	TABLET, FILM COATED	1 g	ORAL	ANDA	20 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-5211	TABLET, FILM COATED	1 g	ORAL	ANDA	20 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-5211	TABLET, FILM COATED	1 g	ORAL	ANDA	20 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-5212	SUSPENSION	5 g	ORAL	ANDA	14 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-5212	SUSPENSION	5 g	ORAL	ANDA	14 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-5213	SUSPENSION	5 g	ORAL	ANDA	14 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0115-5213	SUSPENSION	5 g	ORAL	ANDA	14 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0610	TABLET	1 g	ORAL	NDA authorized generic	19 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0260	GRANULE, FOR SUSPENSION	5 g	ORAL	NDA AUTHORIZED GENERIC	19 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0260	GRANULE, FOR SUSPENSION	5 g	ORAL	NDA AUTHORIZED GENERIC	19 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0450	TABLET	1 g	ORAL	NDA AUTHORIZED GENERIC	19 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	59762-0450	TABLET	1 g	ORAL	NDA AUTHORIZED GENERIC	19 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	60687-715	TABLET, FILM COATED	1 g	ORAL	ANDA	19 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	62559-395	TABLET, FILM COATED	1 g	ORAL	ANDA	16 sections
Colestipol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68151-4361	TABLET	1 g	ORAL	NDA AUTHORIZED GENERIC	18 sections
COLESTIPOL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2693	TABLET, FILM COATED	1 g	ORAL	ANDA	19 sections
Colestipol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70710-1467	TABLET, FILM COATED	1 g	ORAL	ANDA	16 sections
Colestipol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1653	TABLET, FILM COATED	1 g	ORAL	ANDA	1 sections
Colestipol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1653	TABLET, FILM COATED	1 g	ORAL	ANDA	1 sections